Celcuity Inc. Common Stock
$80.61
-$4.30 (-5.06%)
$79.77Day Range$85.17
Key Statistics
Market Cap
$4.15B
Shares Outstanding
48.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 20, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$84.89
Day High
$85.17
Day Low
$79.77
Volume
1.41M
VWAP
$81.02
Prev Close
$84.91
Transactions
--
Acc. Volume
--
About Celcuity Inc. Common Stock
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
SERVICES-MEDICAL LABORATORIESSIC 8071155 employees16305 36TH AVENUE N, MINNEAPOLIS, MN, 55446763-392-0767IPO Sep 20, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001603454
- Composite FIGI
- BBG00HKBW045
- Share Class FIGI
- BBG00HKBW054
- Ticker Root
- CELC
- SIC Code
- 8071
About Celcuity Inc. Common Stock (CELC) Stock
Celcuity Inc. Common Stock (CELC) closed the 2026-09-18 session at $80.61, down 5.06% versus the previous close (-4.30). The stock opened at $84.89 and traded between $79.77 and $85.17 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $81.02.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity Inc. Common Stock has a market capitalization of $4.15 billion. The company operates in the SERVICES-MEDICAL LABORATORIES industry classification. CELC is listed on the XNAS exchange. The company employs approximately 155 people. Celcuity Inc. Common Stock is headquartered in MINNEAPOLIS, MN. The recorded listing date is 2017-09-20.
On this page you can find market CELC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-MEDICAL LABORATORIES sector.